FULC — Fulcrum Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$3.85
-$0.02 (-0.39%)
Fulcrum Therapeutics Inc (FULC) is a biotechnology company listed on NASDAQ. It is led by Alexander C. Sapir, based in 26 Landsdowne Street, Cambridge, MA, United States, 02139, with about 45 employees. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Net income was -$54.5M. FULC currently screens at market cap $427.0M.
Use this FULC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FULC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FULC SEC filings page. Lician reads the product cache first so this HTML stays unique to Fulcrum Therapeutics Inc even when a live quote feed is slow.
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC Key Statistics
Market Cap
$426.98M
Volume
1.32M
Previous Close
$3.84
Day Range
$3.83 – $3.89
EPS
-$0.16
Revenue
$0.00
Net Income
-$9.72M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
45
FULC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.72M | -$97.33M | -$109.87M | -$80.85M |
| EPS (Diluted) | -$0.16 | -$1.59 | -$2.44 | -$2.29 |
Total Assets
$260.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$58.21M
Operating Cash Flow
-$2.22M
Free Cash Flow
$0.00
Fulcrum Therapeutics Inc Company Information
- CEO, President & Director
- Alexander C. Sapir
- Headquarters
- 26 Landsdowne Street, Cambridge, MA, United States, 02139
- Website
- www.fulcrumtx.com
- Phone
- 617 651 8851
- IPO / Founded
- 2019-07-18
- Sector
- Healthcare
- Industry
- Biotechnology